News Release

New malaria test kit gives a boost to elimination efforts worldwide

LAMP test will also improve diagnosis for imported UK cases

Peer-Reviewed Publication

London School of Hygiene & Tropical Medicine

A new, highly sensitive blood test that quickly detects even the lowest levels of malaria parasites in the body could make a dramatic difference in efforts to tackle the disease in the UK and across the world, according to new research published in the Journal of Infectious Diseases.

In two studies led by researchers in the UK and Switzerland, the new LAMP (loop-mediated isothermal amplification) test was compared to existing methods in London laboratories that deal with imported cases of malaria to the UK, and to diagnostic methods used in the field in Uganda, where malaria is a leading cause of illness and death.

The simple test, which can be performed by a non-specialist health worker and does not need refrigerating like other tests, requires a sample of blood to be processed and placed in a test tube with a reactive powder then heated. If the malaria-causing Plasmodium parasites are present, the tube glows green. The whole process takes less than an hour.

The first study, led in London by the Hospital for Tropical Diseases (HTD), the London School of Hygiene & Tropical Medicine and the Foundation for Innovative New Diagnostics (FIND), compared LAMP to existing laboratory diagnostic methods on 705 blood samples of suspected imported malaria cases in the UK.

Dr Colin Sutherland, Clinical Scientist at HTD and Reader in Parasitology at the Malaria Reference Laboratory at the London School of Hygiene & Tropical Medicine, said: "According to data collected for Public Health England by the London School of Hygiene & Tropical Medicine, the UK treats at least 1,500 cases of imported malaria every year. Despite the very best efforts of the NHS, a handful of malaria related deaths still occur annually in UK hospitals. The new LAMP test for malaria performed very well when tested in the parasite reference laboratory at HTD, and correctly identified every malaria patient out of 705 malaria tests performed.

"An important advantage of LAMP is that non-specialist staff in any hospital in the UK will be able to accurately and rapidly detect the presence of malaria parasites, and immediately begin treatment without waiting for confirmation from local experts or specialist laboratories. This speed of diagnosis can make the difference between an uncomplicated episode of malaria that rapidly responds to treatment, and progression to severe disease, organ failure and heightened risk of death. It could also save the NHS a significant amount of money from having to treat the complications of malaria."

LAMP was faster than PCR (polymerase chain reaction) tests, which require specialised laboratory equipment, costly reagents and advanced training. It was also more accurate than microscopic examination of blood slides, which require a trained specialist to identify the malaria parasites.

In the second study, researchers from HTD, FIND, the London School of Hygiene & Tropical Medicine and the Uganda Ministry of Health, Kampala, looked at the accuracy of the test at a rural clinic in Uganda.

Blood samples from 272 patients with suspected malaria were tested using LAMP using a simple generator to provide electrical current. These results were compared with expert microscopy and PCR performed at central reference laboratories. LAMP detected cases of low-level malaria parasite infection that were missed by expert microscopy, and achieved accuracy similar to that of PCR down to very low levels. The researchers say these findings have important implications for eliminating malaria, which causes an estimated 660,000 deaths worldwide every year.

Dr Sutherland, who worked on both of the studies, said: "Patterns of malaria disease in Africa and elsewhere across the tropics are becoming much less predictable, and control of malaria needs an appropriate test to identify infected individuals in the populations at risk. These people may not display any malaria symptoms. We have begun using LAMP as a new tool for identifying "hot spots" of malaria infections which can be mopped up quickly through a combination of drug treatment, house spraying and distribution of bed-nets.

"LAMP will potentially contribute to saving many families and communities from the blight of a disease that keeps children from succeeding at school, prevents adults from growing food or working, holds back regional economies and exacts an annual death toll in the hundreds of thousands."

The LAMP malaria test will now be used in the Malaria Reference Laboratory at the London School of Hygiene & Tropical Medicine to help identify imported cases of malaria in the UK as well as being used by health workers in the field in malaria endemic countries.


The LAMP malaria test is commercially available and was developed by the Foundation for Innovative New Diagnostics, the Hospital for Tropical Diseases, London and Eiken Chemical Company Ltd, Japan. The studies were funded by the Bill and Melinda Gates Foundation, the Ministry of Foreign Affairs of the Government of The Netherlands, and the UK Department for International Development.

For further information or to request interviews, please contact the London School of Hygiene & Tropical Medicine press office on +44 (0) 207 297 2802 or

  • First study: Polley, González, Mohamed, Daly, Bowers, Watson, Armstrong, Gray, Perkins, Bell, Kanda, Tomita, Kubota, Mori, Chiodini, Sutherland. Clinical Evaluation of a LAMP test kit for Diagnosis of Imported Malaria. Journal of Infectious Diseases. DOI: 10.1093/infdis/jit183

  • Second study: Hopkins, González, Polley, Angutoko,Ategeka, Asiimwe, Agaba, Kyabayinze, Sutherland, Perkins, Bell. Highly sensitive detection of malaria parasitemia in an endemic setting: Performance of a new LAMP kit in a remote clinic in Uganda. Journal of Infectious Diseases. DOI: 10.1093/infdis/jit184

London School of Hygiene & Tropical Medicine

The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with 3,500 students and more than 1,000 staff working in over 100 countries. The School is one of the highest-rated research institutions in the UK, and was recently cited as one of the world's top universities for collaborative research. The School's mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice.

Hospital for Tropical Diseases

Part of UCLH (University College London Hospitals NHS Foundation Trust), the Hospital for Tropical Diseases is the only hospital dedicated to tropical and infectious diseases within the NHS. It offers expert advice, diagnosis and treatment for a wide range of infectious and travel-related illnesses including parasites, malaria, leprosy, and diseases of the skin, eye and gut. The hospital serves long and short-term travellers and immigrants It has a daily walk-in emergency clinic for tropical diseases as well as a rapid-access clinic for infectious diseases, specialist outpatient clinics and a clinic for pre-travel advice and vaccinations. For more information visit

Foundation for Innovative New Diagnostics

The Foundation for Innovative New Diagnostics (FIND) is dedicated to developing affordable, easy-to-use, cutting edge diagnostic tests that save lives in the poorest areas of the world. From proof of principle to putting new tests into practice, the organization works with diverse groups, including academia, industry, donors, partners in the field, Ministries of Health and the World Health Organization. With new diagnostics for malaria, tuberculosis and sleeping sickness already in use, FIND is also working on other neglected diseases such leishmaniasis, Chagas disease, and other causes of acute fever. Launched in 2003, the not-for-profit Foundation is ISO certified and financed by both the private and public sectors, including the Bill & Melinda Gates Foundation, the governments of the Netherlands and Germany, the European Union, UNITAID, UK Department for International Development, National Institutes of Health (USA), UBS Optimus Foundation and others.


Eiken Chemical Co., Ltd., has over 60 years of experience in medical diagnostics, and was the first Japanese company to successfully commercialize the manufacture of powdered culture media for microbiological investigations. The company has established itself as a leader in the clinical diagnostics market, and has a strong commitment to research and development toward products and technologies that fill needs at the cutting edge of contemporary medicine. The LAMP technology, developed at Eiken in 1998, is now a core technology being exploited to develop a range of products.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.